William Dale joined City of Hope as a clinical professor in the Department of Supportive Care Medicine.Dale is a board-certified geriatrician and palliative medicine physician with a doctorate in health policy. He completed his medical and graduate school training at the University of Chicago and did his residency in internal medicine and fellowship training in geriatrics at the University of Pittsburgh.
Deric Savior has been promoted to head of medical oncology at Fox Chase Cancer Center at Temple University Hospital.
Carlyn Tan has joined the department of hematology/oncology at Fox Chase Cancer Center.
Reza Nejati was hired as a hematopathologist in the department of pathology at the Fox Chase Cancer Center.
The Cancer Prevention and Research Institute of Texas awarded 60 new academic research, centered around cancer prevention, and product development research grants totaling more than $102 million.CPRIT has awarded 1,189 grants totaling more than $1.89 billion. The agency began making awards in 2009 after Texas voters overwhelmingly approved a 2007 constitutional amendment committing $3 billion to the fight against cancer. Fifty-one of the awards, totaling more than $79 million, went to academic research grants/ Eight prevention services grants were awarded totaling $14 million, as well as one product development research grant for $9 million.“The large number of awards approved by CPRIT underlies the growth of the cancer-fighting ecosystem in Texas,” said Wayne Roberts, CPRIT chief executive officer. “This momentum is evident as Texas expands its critical mass of talent in our life-sciences sector.”
Genentech, a member of the Roche Group, said FDA has accepted the company's supplemental Biologics License Application and granted priority review for Gazyva (obinutuzumab) in combination with chemotherapy followed by Gazyva alone for people with previously untreated follicular lymphoma.
FDA approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.The agent is sponsored by Pfizer Inc.
Kymriah (tisagenlecleucel) became the first gene therapy available in the United States.
FDA approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML).
FDA granted regular approval to olaparib tablets (Lynparza) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. FDA granted this application Fast Track status.
